Detalhe da pesquisa
1.
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
N Engl J Med
; 373(7): 621-31, 2015 Aug 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-26035255
2.
Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM.
Blood
; 127(23): 2833-40, 2016 06 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27091875
3.
Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth.
Br J Haematol
; 178(6): 896-905, 2017 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-28677826
4.
Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma.
Br J Haematol
; 175(3): 448-456, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27434748
5.
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.
N Engl J Med
; 362(24): 2260-70, 2010 Jun 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-20525995
6.
Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Eur J Cancer
; 160: 112-133, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34840026
7.
Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma.
Blood Adv
; 4(21): 5414-5424, 2020 11 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33147337
8.
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
N Engl J Med
; 354(24): 2531-41, 2006 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-16775234
9.
Industry's Giant Leap Into Cellular Therapy: Catalyzing Chimeric Antigen Receptor T Cell (CAR-T) Immunotherapy.
Curr Hematol Malig Rep
; 14(1): 47-55, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30666506
10.
Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study.
Int J Hematol
; 105(3): 326-334, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-27848182
11.
Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study.
Clin Lymphoma Myeloma Leuk
; 16(3): 129-38, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26795075
12.
Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study.
Lancet Haematol
; 2(12): e516-27, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26686406
13.
Phase I dose escalation trial of weekly docetaxel plus irinotecan in patients with advanced cancer.
Cancer Biol Ther
; 1(6): 646-51, 2002.
Artigo
em Inglês
| MEDLINE | ID: mdl-12642688
14.
Camptothecin and taxane regimens for small-cell lung cancer.
Oncology (Williston Park)
; 16(9 Suppl 9): 33-8, 2002 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-12375799
15.
Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia.
Cancer
; 115(13): 2912-21, 2009 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19402171
16.
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R).
Cancer
; 115(18): 4136-47, 2009 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-19536906
17.
Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis.
Cancer Cell
; 14(6): 485-93, 2008 Dec 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-19061839
18.
Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.
J Clin Oncol
; 26(19): 3204-12, 2008 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18541900